Year: 2018

BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB’s 9th Annual Nordic Healthcare Conference

December 12, 2018

Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung…

Read More

BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH

December 3, 2018

43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6…

Read More

BerGenBio appoints cancer drug development specialist Alan Barge MD as interim Chief Medical Officer

November 26, 2018

Further senior organisational changes made in preparation for advancing bemcentinib into the next stage of…

Read More

BerGenBio ASA: Results for the Third Quarter 2018

November 13, 2018

Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated…

Read More

BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC patients in bemcentinib + KEYTRUDA PhII combination trial

November 6, 2018

Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective…

Read More

BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA® in advanced NSCLC at SITC

November 2, 2018

Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading…

Read More